
CORBUS P.H. NEW DL-,0001
Share · US21833P3010 · CRBP · A3D54P (XNCM)
8,08 EUR
06.06.2025 20:15
Current Prices from CORBUS P.H. NEW DL-,0001
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
CRBP
|
USD
|
06.06.2025 20:15
|
9,23 USD
| 8,85 USD
+4,29 %
|
![]() London |
0SZI.L
|
USD
|
06.06.2025 18:16
|
9,09 USD
| 8,85 USD
+2,70 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
-0,45 % | 25,39 % | 37,85 % | 29,60 % | -43,99 % | -80,17 % | -95,72 % |
Company Profile for CORBUS P.H. NEW DL-,0001 Share
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Company Data
Name CORBUS P.H. NEW DL-,0001
Company Corbus Pharmaceuticals Holdings, Inc.
Symbol CRBP
Website
https://www.corbuspharma.com
Primary Exchange
Frankfurt

WKN A3D54P
ISIN US21833P3010
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Dr. Yuval Cohen Ph.D.
Market Capitalization 71 Mio
Country United States of America
Currency EUR
Employees 0,0 T
Address 500 River Ridge Drive, 02062 Norwood
IPO Date 2018-11-23
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 3371.F |
London | 0SZI.L |
NASDAQ | CRBP |
Weitere Aktien
Investoren die CORBUS P.H. NEW DL-,0001 die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.